Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias

NCT04623944 is registered in ClinicalTrials.gov with Nkarta, Inc. as lead sponsor.

NCT NCT04623944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04623944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Lead sponsor
Nkarta, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 21, 2020
Completion date
July 31, 2039
Enrollment
61 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult, mds, refractory myelodysplastic syndromes, relapsed/refractory aml